Modeling the cancer patient with genetically engineered mice: Prediction of toxicity from molecule-targeted therapies

This publication has 52 references indexed in Scilit:

• Inhibiting the p53–MDM2 interaction: an important target for cancer therapy
  Nature Reviews Cancer, 2003
• Colonic Epithelial Expression of ErbB2 Is Required for Postnatal Maintenance of the Enteric Nervous System
  Neuron, 2003
• Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types
  Journal of Clinical Oncology, 2002
• ErbB2 is essential in the prevention of dilated cardiomyopathy
  Nature Medicine, 2002
• Renal Failure Associated with the Use of Celecoxib and Rofecoxib
  Drug Safety, 2002
• Growth retardation and increased apoptosis in mice with homozygous disruption of the akt1 gene
  Genes & Development, 2001
• Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225
  British Journal of Dermatology, 2001
• Mice mutant for Egfr and Shp2 have defective cardiac semilunar valvulogenesis
  Nature Genetics, 2000
• The ErbB2 and ErbB3 receptors and their ligand, neuregulin-1, are essential for development of the sympathetic nervous system
  Genes & Development, 1998
• Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II
  Nature, 1995